

Article 34

0/527694
DT09 Rec'd PCT/PTO 11 MAR 2005

AMENDMENT

(Amendment under the provision of Law Section 11)

To: Commissioner of the Patent Office

1. Identification of the International Application

PCT/JP03/11669

2. Applicant

Name: National Institute for Materials Science

Address: 2-1, Sengen 1-chome, Tsukuba-shi, Ibaraki 305-
0047 Japan

Country of nationality: Japan

Country of residence: Japan

3. Agent

Name: Patent Attorney, NISHI Yoshiyuki (10867)

Address: Nishi Patent Office, Suite 211, 26-32,
Nakahara 4-chome, Isogo-ku, Yokohama-shi,
Kanagawa 235-0036 Japan

4. Item to be Amended

Claims

5. Subject Matter of Amendment

(1) In claim 1, "2-ketoglutaric acid" is deleted.

Article 34

(2) In claim 1, "derivative thereof" is amended to "derivative thereof, wherein the biological low-molecular-weight derivative undergoes hydrolyzation in vivo after application in vivo and reacts with a biological high-molecular-weight compound".

(3) In claim 4, "the biological low-molecular-weight derivative according to claim 1." is amended to "the biological low-molecular-weight derivative according to claim 1, the crosslinked high-molecular-weight product comprising a gel that is metabolized in vivo after application in vivo".

(4) New claims 8 to 11 are added.

6. List of Attached Documents

(1) Claims: page 13, page 13/1, page 14

replaced
by Article 34

CLAIMS

1. A biological low-molecular-weight derivative obtained by modifying at least one carboxyl group of a biological low-molecular-weight compound having two or more carboxyl groups with N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or a derivative thereof.

2. The biological low-molecular-weight derivative according to claim 1, wherein the biological low-molecular-weight compound having two or more carboxyl groups is a low-molecular-weight compound in the citric acid cycle or a derivative thereof.

3. The biological low-molecular-weight derivative according to claim 1, wherein the biological low-molecular-weight compound having two or more carboxyl groups is malic acid, oxalacetic acid, citric acid, cis-aconitic acid, 2-ketoglutaric acid, or a derivative thereof.

4. A crosslinked high-molecular-weight product obtained by crosslinking a high-molecular-weight compound with the biological low-molecular-weight derivative according to claim 1.

5. The crosslinked high-molecular-weight product according to claim 4, wherein the high-molecular-weight compound is at least one of proteins, glycosaminoglycans,

replaced by
Article 34

chitosans, polyamino acids, and polyalcohols.

6. The crosslinked high-molecular-weight product according to claim 4, wherein the high-molecular-weight
5 compound is a glycosaminoglycan comprising chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparan sulfate, heparin, keratan sulfate, or a derivative thereof.

7. The crosslinked high-molecular-weight product
10 according to claim 4, wherein the high-molecular-weight compound is a protein comprising collagen, atelocollagen, alkali-soluble collagen, gelatin, keratin, serum albumin, egg albumin, hemoglobin, casein, globulin, fibrinogen, or a derivative thereof.